Cargando…
Protocol of Pakistan randomized and observational trial to evaluate coronavirus treatment among newly diagnosed patients with COVID-19: Azithromycin, Oseltamivir, and Hydroxychloquine
BACKGROUND & OBJECTIVE: This study aimed to assess the clinical effectiveness of Hydroxychloroquine Sulfate (200 mg orally 8 hourlies thrice a day for 5 days), oseltamivir (75 mg orally twice a day for 5 days), and Azithromycin (500 mg orally daily on day 1, followed by 250 mg orally twice a day...
Autores principales: | Azhar, Shehnoor, Akram, Javed, Shahzad, Muhammad, Latif, Waqas, Khan, Khalid Saeed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Professional Medical Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247782/ https://www.ncbi.nlm.nih.gov/pubmed/35799756 http://dx.doi.org/10.12669/pjms.38.5.5512 |
Ejemplares similares
-
Correction to: Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection: A structured summary of a study protocol for a randomized controlled trial
por: Akram, Javed, et al.
Publicado: (2020) -
Correction to: Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection: A structured summary of a study protocol for a randomized controlled trial
por: Akram, Javed, et al.
Publicado: (2022) -
Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial
por: Akram, Javed, et al.
Publicado: (2020) -
Patient safety attitudes of frontline healthcare workers in Lahore: A multicenter study
por: Arkam, Javed, et al.
Publicado: (2022) -
Azithromycin/hydroxychloroquine/oseltamivir: Erythema multiforme major: case report
Publicado: (2021)